BK 1301

Drug Profile

BK 1301

Alternative Names: Adsorbed diphtheria-purified pertussis-tetanus combined vaccine - Mitsubishi Tanabe Pharma; Tribik

Latest Information Update: 12 May 2015

Price : $50

At a glance

  • Originator Mitsubishi Tanabe Pharma Corporation; Research Foundation for Microbial Diseases of Osaka University
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Diphtheria; Pertussis; Tetanus

Most Recent Events

  • 30 Apr 2015 Mitsubishi Tanabe Pharma files sNDA for stage 2 vaccination in prophylaxis of patients with Diphtheria, Pertusis and Tetanus in Japan (Mitsubishi Tanabe Pharma pipeline, May 2015)
  • 01 Aug 2014 Mitsubishi Tanabe Pharma completes a phase III trial in Diphtheria, Pertussis and Tetanus (Prevention, In adolescents) in Japan (NCT02118961)
  • 30 Apr 2014 Mitsubishi Tanabe Pharma in collaboration with the Research Foundation for Microbial Diseases of Osaka University initiates phase-III clinical trials in Tetanus (Prevention, In adolescents) in Japan (SC) (NCT02118961)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top